UPDATED: Not everybody is buying it, but everybody is definitely talking about a new Biogen buyout report
A Korean business publication reported Wednesday that Samsung is in the process of making a buyout bid for Biogen, raising equal parts skepticism and anticipation around a possible deal.
The report from the Korea Economic Daily says that the Samsung Group – which has a long-term biosimilar partnership with Biogen – has offered to acquire Biogen for some $42 billion, a 20% improvement over the $35 billion recorded ahead of the report. That’s far less than what Biogen was trading for when hopes of a major windfall from their controversial Alzheimer’s drug Aduhelm still percolated.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.